-
1دورية أكاديمية
المصدر: Health Promotion Practice; May2024, Vol. 25 Issue 3, p317-321, 5p
مصطلحات موضوعية: PHOTOGRAPHY & psychology, INSTITUTIONAL racism, SOCIAL determinants of health, PATIENT advocacy, COMMUNITIES, REFLECTION (Philosophy), BLACK people, ROOT cause analysis, ACTION research, MEDICAL research, CRITICAL race theory, HEALTH promotion, HEALTH education, STUDENT attitudes, HEALTH equity, PRACTICAL politics, VOCATIONAL guidance
مصطلحات جغرافية: UNITED States
مستخلص: The use of Critical Race Theory, Photovoice, and Community-Based Participatory Research has helped uncover the root causes of issues such as systemic racism in the fields of public health and health promotion. Often, we see studies using traditional research methods to investigate potential causal factors of disparities in minoritized communities report only quantitative data. While these data are imperative for understanding the severity of disparities, quantitative-only approaches cannot address nor can they improve the critical root causes of these disparities. As a team of BIPOC graduate students in public health, we conducted a community-based participatory research project using Photovoice methodology to explore inequities in Black and Brown communities exacerbated during the COVID-19 pandemic. The participatory nature of this research revealed cumulative challenges across the social determinants of health in New Haven and Bridgeport, Connecticut. It allowed us to engage in local-level advocacy to promote health equity as our findings illuminated the need for community-led and community-engaged action. Health and racial inequities cannot be effectively addressed if public health research and programming do not collaborate with the community to build community capacity, empowerment, and trust. We describe our experiences doing community-based participatory research to investigate inequities and provide reflections on their value for public health students. As responses to health inequities and disparities become more politically polarized in the United States, it is critical for public health and health education students to use research methodologies that elevate communities that have been historically marginalized and neglected. Together, we can catalyze equitable change. [ABSTRACT FROM AUTHOR]
: Copyright of Health Promotion Practice is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
-
2دورية
المؤلفون: Abraham, Jean E., Pinilla, Karen, Dayimu, Alimu, Grybowicz, Louise, Demiris, Nikolaos, Harvey, Caron, Drewett, Lynsey M., Lucey, Rebecca, Fulton, Alexander, Roberts, Anne N., Worley, Joanna R., Chhabra, Anita, Qian, Wendi, Vallier, Anne-Laure, Hardy, Richard M., Chan, Steve, Hickish, Tamas, Tripathi, Devashish, Venkitaraman, Ramachandran, Persic, Mojca, Aslam, Shahzeena, Glassman, Daniel, Raj, Sanjay, Borley, Annabel, Braybrooke, Jeremy P., Sutherland, Stephanie, Staples, Emma, Scott, Lucy C., Davies, Mark, Palmer, Cheryl A., Moody, Margaret, Churn, Mark J., Newby, Jacqueline C., Mukesh, Mukesh B., Chakrabarti, Amitabha, Roylance, Rebecca R., Schouten, Philip C., Levitt, Nicola C., McAdam, Karen, Armstrong, Anne C., Copson, Ellen R., McMurtry, Emma, Tischkowitz, Marc, Provenzano, Elena, Earl, Helena M.
المصدر: Nature; May 2024, Vol. 629 Issue: 8014 p1142-1148, 7p
مستخلص: PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1,2, who were germline BRCA1and BRCA2wild type3. Here we report the results of the trial. Patients (n= 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)4, and secondary end points included event-free survival (EFS) and overall survival (OS)5. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P= 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P> 0.9), respectively; OS was 90% and 87.2% (log-rank P= 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P< 0.001), and OS was 96% and 83% (log-rank P< 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin–paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1and BRCA2wild type. ClinicalTrials.gov ID: NCT03150576.
-
3دورية أكاديمية
المؤلفون: Abraham, Jean E, Pinilla, Karen, Dayimu, Alimu, Grybowicz, Louise, Demiris, Nikolaos, Harvey, Caron, Drewett, Lynsey M, Lucey, Rebecca, Fulton, Alexander, Roberts, Anne N, Worley, Joanna R, Chhabra, Anita, Qian, Wendi, Vallier, Anne-Laure, Hardy, Richard M, Chan, Steve, Hickish, Tamas, Tripathi, Devashish, Venkitaraman, Ramachandran, Persic, Mojca, Aslam, Shahzeena, Glassman, Daniel, Raj, Sanjay, Borley, Annabel, Braybrooke, Jeremy P, Sutherland, Stephanie, Staples, Emma, Scott, Lucy C, Davies, Mark, Palmer, Cheryl A, Moody, Margaret, Churn, Mark J, Newby, Jacqueline C, Mukesh, Mukesh B, Chakrabarti, Amitabha, Roylance, Rebecca R, Schouten, Philip C, Levitt, Nicola C, McAdam, Karen, Armstrong, Anne C, Copson, Ellen R, McMurtry, Emma, Tischkowitz, Marc, Provenzano, Elena, Earl, Helena M
مصطلحات موضوعية: Adult, Aged, Female, Humans, Middle Aged, Anthracyclines, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Genes, BRCA1, BRCA2, Neoadjuvant Therapy, Paclitaxel, Pathologic Complete Response, Phthalazines, Piperazines, Progression-Free Survival, Prospective Studies, Survival Analysis, Time Factors, Triple Negative Breast Neoplasms, Adolescent, Young Adult
الوصف: Acknowledgements: We thank the patients, and the families and friends who supported them, for participating in this trial; our ethics committee, our independent data and safety monitoring committee and the trial management group for their advisory roles; the PARTNER trial consortium members, past and present (Supplementary Information); and I. Cizaite for preparing and proofreading the manuscript. This trial was sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, and financed by a project grant from AstraZeneca, who also supplied olaparib. Cancer Research UK provided peer review and endorsement for the study and financed the sample collections for the translational studies, which will be reported separately. We also acknowledge the National Institute for Health and Care Research Cambridge Biomedical Research Centre and the Cancer Research UK Cambridge Centre for their financial support for staff and infrastructure costs. The funders had no role in data collection or analysis. Once the trial group had interpreted the data, the results were then shared with the AstraZeneca scientists. In addition, we thank the Cancer Molecular Diagnostics Laboratory and The Precision Breast Cancer Institute Team for their support for sample collection; Cambridge Tissue Bank (NIHR203312) for sample assessment and diagnostics; Cambridge Clinical Trials Centre – Cancer Theme for their core staff support; the clinical trials support staff at all participating sites; and Addenbrookes Charitable Trust for financing the post of the chief investigator (2015–2018). We acknowledge Cancer Research UK (CRUKE/14/048) and AstraZeneca (1994-A093777). ; PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1,2, who were germline BRCA1 and BRCA2 wild type3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin-paclitaxel with or without 150 mg olaparib ...
وصف الملف: application/zip; text/xml; application/pdf
-
4دورية أكاديمية
المؤلفون: Mendes Serrao, Eva, Joslin, Emily, McMorran, Victoria, Hough, Caroline, Palmer, Cheryl, McDonald, Sarah, Cargill, Emma, Shaw, Ashley S, O'Carrigan, Brent, Parkinson, Christine A, Corrie, Pippa G, Sadler, Timothy J
المصدر: essn: 1470-7330 ; nlmid: 101172931
مصطلحات موضوعية: Aneurysmal, Melanoma, Metastatic, Radiology, Small bowel, Abdomen, Humans, Intestine, Small, Quality of Life, Skin Neoplasms
الوصف: BACKGROUND: Melanoma is the most aggressive form of skin cancer, with a tendency to metastasise to any organ of the human body. While the most common body organs affected include liver, lungs, brain and soft tissues, spread to the gastrointestinal tract is not uncommon. In the bowel, it can present with a multitude of imaging appearances, more rarely as an aneurysmal dilatation. This appearance is classically associated with lymphoma, but it has more rarely been associated with other forms of malignancy. CASE PRESENTATION: We report a case series of three patients with aneurysmal dilatation in the small bowel (SB) confirmed to be due to metastatic melanoma (MM). All patients had non-specific symptoms; most times being attributed initially to causes other than melanoma. On CT the identified aneurysmal SB dilatations were diagnosed as presumed lymphoma in all cases. In two cases, the aneurysmal dilatation was the first presentation of metastatic disease and in two of the cases more than one site of the gastrointestinal tract was concomitantly involved. All patients underwent surgical resection with histological confirmation of MM. CONCLUSIONS: Recognition of unusual SB presentation of MM, such as aneurysmal SB dilatation, is important to expedite diagnosis, provide appropriate treatment, and consequently improve quality of life and likely survival of these patients. As the most common cancer to metastasise to the SB and as a known imaging mimicker, MM should remain in any radiologist's differential diagnosis for SB lesions with aneurysmal dilatation. ; Acknowledgements The authors acknowledge support from National Institute of Health Research Cambridge Biomedical Research Centre, Cancer Research UK (Cambridge Imaging Centre grant number C197/A16465), the Engineering and Physical Sciences Research Council Imaging Centre in Cambridge and Manchester and the Cambridge Experimental Cancer Medicine Centre. Funding source and conflicts of interest E.M.S is funded by NIHR Clinical Lectureship (Reference number: NIHR ...
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.17863/CAM.86590Test
https://www.repository.cam.ac.uk/handle/1810/339180Test -
5دورية أكاديمية
المؤلفون: Kator, Sarah, Zurko, Jessica, Webb, Brandon J., Balatico, Michael A., Clayton, Frederic, Palmer, Cheryl A., Konopa, Kelly, Motyckova, Gabriela, Ford, Clyde D., Ostronoff, Fabiana
المصدر: British Journal of Haematology ; volume 189, issue 1 ; ISSN 0007-1048 1365-2141
-
6دورية أكاديمية
المؤلفون: Cannon-Albright, Lisa A, Farnham, James M, Stevens, Jeffrey, Teerlink, Craig C, Palmer, Cheryl A, Rowe, Kerry, Cessna, Melissa H, Blumenthal, Deborah T
المساهمون: National Cancer Institute
المصدر: Neuro-Oncology ; volume 23, issue 2, page 277-283 ; ISSN 1522-8517 1523-5866
مصطلحات موضوعية: Cancer Research, Neurology (clinical), Oncology
الوصف: Background There is evidence for an inherited contribution to primary brain cancer. Linkage analysis of high-risk brain cancer pedigrees has identified candidate regions of interest in which brain cancer predisposition genes are likely to reside. Methods Genome-wide linkage analysis was performed in a unique set of 11 informative, extended, high-risk primary brain cancer pedigrees identified in a population genealogy database, which include from 2 to 6 sampled, related primary brain cancer cases. Access to formalin-fixed paraffin embedded tissue samples archived in a biorepository allowed analysis of extended pedigrees. Results Individual high-risk pedigrees were singly informative for linkage at multiple regions. Suggestive evidence for linkage was observed on chromosomes 2, 3, 14, and 16. The chromosome 16 region in particular contains a promising candidate gene, pyridoxal-dependent decarboxylase domain-containing 1 (PDXDC1), with prior evidence for involvement with glioblastoma from other previously reported experimental settings, and contains the lead single nucleotide polymorphism (rs3198697) from the linkage analysis of the chromosome 16 region. Conclusions Pedigrees with a statistical excess of primary brain cancers have been identified in a unique genealogy resource representing the homogeneous Utah population. Genome-wide linkage analysis of these pedigrees has identified a potential candidate predisposition gene, as well as multiple candidate regions that could harbor predisposition loci, and for which further analysis is suggested.
الإتاحة: https://doi.org/10.1093/neuonc/noaa161Test
http://academic.oup.com/neuro-oncology/article-pdf/23/2/277/36356969/noaa161.pdfTest -
7دورية أكاديمية
المؤلفون: Ponnapalli, Sri Priya, Bradley, Matthew W., Devine, Karen, Bowen, Jay, Coppens, Sara E., Leraas, Kristen M., Milash, Brett A., Li, Fuqiang, Luo, Huijuan, Qiu, Shi, Wu, Kui, Yang, Huanming, Wittwer, Carl T., Palmer, Cheryl A., Jensen, Randy L., Gastier-Foster, Julie M., Hanson, Heidi A., Barnholtz-Sloan, Jill S., Alter, Orly
المساهمون: National Cancer Institute, Utah Science Technology and Research, NIH Office of the Director
المصدر: APL Bioengineering ; volume 4, issue 2 ; ISSN 2473-2877
مصطلحات موضوعية: Biomedical Engineering, Biomaterials, Biophysics, Bioengineering
الوصف: Modeling of genomic profiles from the Cancer Genome Atlas (TCGA) by using recently developed mathematical frameworks has associated a genome-wide pattern of DNA copy-number alterations with a shorter, roughly one-year, median survival time in glioblastoma (GBM) patients. Here, to experimentally test this relationship, we whole-genome sequenced DNA from tumor samples of patients. We show that the patients represent the U.S. adult GBM population in terms of most normal and disease phenotypes. Intratumor heterogeneity affects ≈11% and profiling technology and reference human genome specifics affect <1% of the classifications of the tumors by the pattern, where experimental batch effects normally reduce the reproducibility, i.e., precision, of classifications based upon between one to a few hundred genomic loci by >30%. With a 2.25-year Kaplan–Meier median survival difference, a 3.5 univariate Cox hazard ratio, and a 0.78 concordance index, i.e., accuracy, the pattern predicts survival better than and independent of age at diagnosis, which has been the best indicator since 1950. The prognostic classification by the pattern may, therefore, help to manage GBM pseudoprogression. The diagnostic classification may help drugs progress to regulatory approval. The therapeutic predictions, of previously unrecognized targets that are correlated with survival, may lead to new drugs. Other methods missed this relationship in the roughly 3B-nucleotide genomes of the small, order of magnitude of 100, patient cohorts, e.g., from TCGA. Previous attempts to associate GBM genotypes with patient phenotypes were unsuccessful. This is a proof of principle that the frameworks are uniquely suitable for discovering clinically actionable genotype–phenotype relationships.
-
8دورية أكاديمية
المؤلفون: Robinson, Lorraina J, Sudarshan, Duncan, Goold, Eric, Comstock, Jessica, Klonoski, Joshua, Mao, Qinwen, Palmer, Cheryl A, Davidson, Christian
المصدر: Journal of Neuropathology & Experimental Neurology; Oct2023, Vol. 82 Issue 10, p880-883, 4p
-
9دورية أكاديمية
المؤلفون: Whalley, W. Brian, Palmer, Cheryl F.
المصدر: Geografiska Annaler. Series A, Physical Geography, 1998 Jan 01. 80(3/4), 221-236.
الوصول الحر: https://www.jstor.org/stable/521060Test
-
10دورية أكاديمية
المساهمون: Connecticut Health Foundation
المصدر: Health Promotion Practice ; volume 25, issue 3, page 317-321 ; ISSN 1524-8399 1552-6372
الوصف: The use of Critical Race Theory, Photovoice, and Community-Based Participatory Research has helped uncover the root causes of issues such as systemic racism in the fields of public health and health promotion. Often, we see studies using traditional research methods to investigate potential causal factors of disparities in minoritized communities report only quantitative data. While these data are imperative for understanding the severity of disparities, quantitative-only approaches cannot address nor can they improve the critical root causes of these disparities. As a team of BIPOC graduate students in public health, we conducted a community-based participatory research project using Photovoice methodology to explore inequities in Black and Brown communities exacerbated during the COVID-19 pandemic. The participatory nature of this research revealed cumulative challenges across the social determinants of health in New Haven and Bridgeport, Connecticut. It allowed us to engage in local-level advocacy to promote health equity as our findings illuminated the need for community-led and community-engaged action. Health and racial inequities cannot be effectively addressed if public health research and programming do not collaborate with the community to build community capacity, empowerment, and trust. We describe our experiences doing community-based participatory research to investigate inequities and provide reflections on their value for public health students. As responses to health inequities and disparities become more politically polarized in the United States, it is critical for public health and health education students to use research methodologies that elevate communities that have been historically marginalized and neglected. Together, we can catalyze equitable change.
